Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Ward Knutson who wrote (7747)	3/18/2000 6:22:00 PM
From: Vector1	Read Replies (1) \| Respond to of 9719

Ward, At this point it looks to me like MGI 114 has real potential as a niche cancer drug used in combo treatment until revolutionary new molecules come along. A niche drug for refactory patients in various cancers is nothing to scoff at and the sales if approved could be be in the several hunded million range after two or three years. It is critical to understand MGI 114's mechanism of action so that analogs can be derived that are more specific and have fewer dose limiting side effects. V1